- |||||||||| aldoxorubicin (INNO-206) / ImmunityBio
Journal: Physalis Mottle Virus-Like Nanocarriers with Expanded Internal Loading Capacity. (Pubmed Central) - Aug 24, 2023 Specifically, the A31C and S137C mutants show a greater than 10-fold increased rate of reactivity towards thiol-reactive small molecules, and PhMV Cys1 (A31C), PhMV Cys2 (S137C), and PhMV Cys1+2 (double mutant) VLPs display up to three-fold increased internal loading of the small molecule chemotherapeutics aldoxorubicin and vcMMAE and up to four-fold increased internal loading of the MRI imaging reagent DOTA(Gd). These results further improve upon a promising plant virus-based nanocarrier system for use in targeted delivery of small-molecule drugs and imaging reagents in vivo.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity. (Pubmed Central) - Jun 19, 2022 SynB1-ELP1-DOXO biopolymers demonstrated a 6-fold increase in tumor/heart ratio in comparison to free doxorubicin, indicating preferential accumulation of the drug in tumors. These results demonstrate that thermally targeted polymers are a promising therapy to enhance tumor targeting and uptake of anticancer drugs and to minimize free drug toxicity in healthy tissues, representing a great potential for clinical application.
- |||||||||| Trial completion date, Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Mar 29, 2022
P1b/2, N=332, Active, not recruiting, Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| aldoxorubicin (INNO-206) / ImmunityBio
Journal: Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy. (Pubmed Central) - Oct 16, 2021 M1 macrophage-derived EVs (M1 EVs) are simultaneously loaded with bis[2,4,5-trichloro-6-(pentyloxycarbonyl) phenyl] oxalate (CPPO), chlorin e6 (Ce6), and prodrug aldoxorubicin (Dox-EMCH)...Meanwhile, O -induced membrane rupture leads to the release of Dox-EMCH, which is then activated and penetrates the deep hypoxic areas of tumors. The synergism of immunotherapy, PDT, and chemotherapy results in potent anticancer efficacy, showing great promise to fight cancers.
- |||||||||| PD-L1.t-haNK / ImmunityBio, aldoxorubicin (INNO-206) / LadRx, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion date, Trial primary completion date, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 5, 2021 P2, N=248, Recruiting, The synergism of immunotherapy, PDT, and chemotherapy results in potent anticancer efficacy, showing great promise to fight cancers. Trial completion date: Jun 2022 --> Sep 2024 | Trial primary completion date: Jun 2021 --> Jun 2024
- |||||||||| aldoxorubicin (INNO-206) / ImmunityBio
Journal: Improving Bioavailaibity of Hydrophobic Prodrugs through Supramolecular Nanocarriers based on Recombinant Proteins for Osteosarcoma Treatment. (Pubmed Central) - Aug 11, 2021 Here, we developed a new generation of recombinant protein-based nanodrug carriers, which is very efficient for loading and delivering the hydrophobic prodrug aldoxorubicin...Importantly, off-target side effects of the prodrug including cardiotoxicity and lung-metastasis were greatly mitigated with our medication. Thus, our assembly strategy potently enables customized designs of advanced nanodelivery systems employing broader biomaterial building blocks for cancer therapy.
- |||||||||| aldoxorubicin (INNO-206) / ImmunityBio
Aldoxorubicin?!! (Twitter) - Jul 7, 2021
|